Genentech Submits Supplemental Biologics License Application for Avastin(R) With Chemotherapy in First-Line, (FinanzNachrichten)
SOUTH SAN FRANCISCO, Calif., April 11 /PRNewswire-FirstCall/ -- Genentech, ( Nachrichten ) Inc. announced today that the company submitted a supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration (FDA) for Avastin(R) (bevacizumab) in combination with platinum-based chemotherapy for first-line treatment of advanced, non- squamous, non-small cell lung cancer

Targacept, Vanda Decline in Trading Debuts (Minneapolis-St. Paul Star Tribune)
WASHINGTON (AP) - Two drug discovery companies' initial public offerings fell Wednesday, as investors avoided higher-risk offerings. Biopharmaceutical company Targacept Inc. and Vanda Pharmaceuticals Inc. both priced $2 below their lowest expected ranges, and then went on to post declines in their first day of trading. Shares of Targacept fell 50 cents, or 5.6 percent, to $8.50 in early afternoon